儿童至成人急性淋巴细胞白血病中门冬酰胺酶相关胰腺炎:NOPHO ALL2008 研究结果
该前瞻性研究纳入2008年7月至2018年10月诊断的2448例1.0-45.9岁急性淋巴细胞白血病患者,按NOPHO ALL2008方案治疗,登记168例门冬酰胺酶相关胰腺炎(AAP)。青少年和成人AAP风险相似且高于儿童,青少年并发症最重;
要点
- 青少年和成人AAP风险相似,均高于1.0-9.9岁儿童。
- 青少年急性及持续性并发症风险均高于儿童,成人仅持续性并发症风险增高。
- 再暴露患者中近半数发生第二次AAP,再暴露仅应考虑高复发风险者。
核心结论
- 较大儿童和成人AAP风险相似,而并发症在青少年中最突出。
- 门冬酰胺酶再暴露应仅考虑预期高白血病复发风险的患者。
- AAP或门冬酰胺酶截断未与复发风险增加相关。
研究设计与样本
- 前瞻性登记研究,纳入2008年7月至2018年10月诊断的2448例1.0-45.9岁ALL患者,按NOPHO ALL2008方案治疗。
- 登记AAP 168例。
临床怎么用
- 对青少年和成人ALL患者应警惕AAP风险,青少年尤其关注急性及持续性并发症。
- 门冬酰胺酶再暴露仅用于预期高白血病复发风险者,因减少治疗强度可能增加复发风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Asparaginase-associated pancreatitis (AAP) is common in patients with acute lymphoblastic leukemia (ALL), but risk differences across age groups both in relation to first-time AAP and after asparaginase re-exposure have not been explored. PATIENTS AND METHODS: We prospectively registered AAP (n = 168) during treatment of 2,448 consecutive ALL patients aged 1.0-45.9 years diagnosed from July 2008 to October 2018 and treated according to the Nordic Society of Pediatric Hematology and Oncology (NOPHO) ALL2008 protocol. RESULTS: Compared with patients aged 1.0-9.9 years, adjusted AAP hazard ratios (HRa) were associated with higher age with almost identical HRa (1.6; 95% CI, 1.1 to 2.3; P = .02) for adolescents (10.0-17.9 years) and adults (18.0-45.9 years). The day 280 cumulative incidences of AAP were 7.0% for children (1.0-9.9 years: 95% CI, 5.4 to 8.6), 10.1% for adolescents (10.0 to 17.9 years: 95% CI, 7.0 to 13.3), and 11.0% for adults (18.0-45.9 years: 95% CI, 7.1 to 14.9; P = .03). Adolescents had increased odds of both acute (odds ratio [OR], 5.2; 95% CI, 2.1 to 13.2; P = .0005) and persisting complications (OR, 6.7; 95% CI, 2.4 to 18.4; P = .0002) compared with children (1.0-9.9 years), whereas adults had increased odds of only persisting complications (OR, 4.1; 95% CI, 1.4 to 11.8; P = .01). Fifteen of 34 asparaginase-rechallenged patients developed a second AAP. Asparaginase was truncated in 17/21 patients with AAP who subsequently developed leukemic relapse, but neither AAP nor the asparaginase truncation was associated with increased risk of relapse. CONCLUSION: Older children and adults had similar AAP risk, whereas morbidity was most pronounced among adolescents. Asparaginase re-exposure should be considered only for patients with an anticipated high risk of leukemic relapse, because multiple studies strongly indicate that reduction of asparaginase treatment intensity increases the risk of relapse.
引用
- Rank CU, Wolthers BO, Grell K, et al. Asparaginase-Associated Pancreatitis in Acute Lymphoblastic Leukemia: Results From the NOPHO ALL2008 Treatment of Patients 1-45 Years of Age. J Clin Oncol. 2019. PMID: 31770057. doi:10.1200/JCO.19.02208
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。